Mink therapeutics announces virtual annual shareholders meeting

New york, may 25, 2022 (globe newswire) -- mink therapeutics, inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, announced that its virtual-only annual meeting of shareholders will be held at 5:00 pm et on june 8, 2022.
INKT Ratings Summary
INKT Quant Ranking